Kite Winds Up Phase 1 of Leukemia Med Trial

— Data Show High Rates of Response to Single Infusion of KTE-X19 —

— Phase 2 Portion of ZUMA-3 is Ongoing and Includes Dosing and Revised Safety Management Protocol Studied in Phase 1 —

Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy. ZUMA-3 is a single-arm Phase 1/2 study in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The results provide guidance on dosing and safety management for KTE-X19 to inform the ongoing Phase 2 study. The data were presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 – June 4 (Abstract #7006).

https://www.marketscreener.com/GILEAD-SCIENCES-4876/news/Gilead-Sciences-Kite-Announces-End-of-Phase-1-ZUMA-3-Results-for-KTE-X19-in-Adult-Patients-with-Re-28692908/